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Inflammatory conditions characterized by excessive immune cell activation and cytokine release,
are associated with bidirectional immune system-brain communication, underlying sickness
behavior and other physiological responses. The vagus nerve has an important role in this
communication by conveying sensory information to the brain, and brain-derived
immunoregulatory signals that suppress peripheral cytokine levels and inflammation. Brain
muscarinic acetylcholine receptor (mAChR)-mediated cholinergic signaling has been implicated
in this regulation. However, the possibility of controlling inflammation by peripheral
administration of centrally-acting mAChR agonists is unexplored. To provide insight we used the
centrally-acting M1 mAChR agonist xanomeline, previously developed in the context of
Alzheimer’s disease and schizophrenia. Intraperitoneal administration of xanomeline significantly
suppressed serum and splenic TNF levels, alleviated sickness behavior, and increased survival
during lethal murine endotoxemia. The anti-inflammatory effects of xanomeline were brain
mAChR-mediated and required intact vagus nerve and splenic nerve signaling. The antiinflammatory efficacy of xanomeline was retained for at least 20h, associated with alterations in
splenic lymphocyte, and dendritic cell proportions, and decreased splenocyte responsiveness to
endotoxin. These results highlight an important role of the M1 mAChR in a neural circuitry to
spleen in which brain cholinergic activation lowers peripheral pro-inflammatory cytokines to
levels favoring survival. The therapeutic efficacy of xanomeline was also manifested by
significantly improved survival in preclinical settings of severe sepsis. These findings are of
interest for strategizing novel therapeutic approaches in inflammatory diseases.
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1. Introduction
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The release of cytokines is an important constituent of innate immune activation and
protective inflammatory responses triggered by infection or tissue damage (Tracey, 2002).
However, the overproduction of TNF and other pro-inflammatory cytokines by activated
macrophages and other immune cells, and their systemic release can be deleterious and
associated with development of inflammatory disorders (Tracey, 2002). Therefore,
preventing and neutralizing excessive pro-inflammatory cytokine release is an important
therapeutic strategy in inflammatory diseases (Tracey, 2002). Inflammatory conditions are
associated with bidirectional immune system-brain communication (Goehler et al.,
2000;Kelley and McCusker, 2014;Tracey, 2002;McCusker and Kelley, 2013;Steinman,
2012;Capuron and Miller, 2011;Raison and Miller, 2013). Excessive pro-inflammatory
cytokine release frequently results in alterations of brain function, manifested by fever and
sickness behavior, and the vagus nerve plays a mediating role in conveying cytokine signals
to the brain (Goehler et al., 1999;Goehler et al., 2000;Kelley and McCusker,
2014;McCusker and Kelley, 2013). Brain-derived neural anti-inflammatory mechanisms
function to suppress peripheral cytokine responses (Pavlov et al., 2003;Kelley and
McCusker, 2014;Tracey, 2009;Pavlov and Tracey, 2004;Olofsson et al., 2012). Efferent
vagus nerve-splenic nerve interaction within the cholinergic anti-inflammatory pathway is
an essential constituent of these mechanisms during endotoxemia and other inflammatory
conditions (Pavlov and Tracey, 2005;Pavlov and Tracey, 2006;Tracey, 2007;Rosas-Ballina
et al., 2008;Rosas-Ballina et al., 2011). Accordingly, vagus nerve stimulation and
cholinergic modalities have been implicated in the experimental treatment of several
inflammatory conditions, including sepsis, inflammatory bowel disease, rheumatoid
arthritis, obesity, and type 2 diabetes (Pavlov, 2008;Pavlov and Tracey, 2012;Satapathy et
al., 2011;Andersson and Tracey, 2012;Ji et al., 2014).
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The neural regulation of inflammation is integrated in the brain, and brain muscarinic
acetylcholine receptors (mAChRs) have been implicated in the neural control of peripheral
pro-inflammatory cytokine levels (Pavlov et al., 2006;Ji et al., 2014). However, the antiinflammatory efficacy of peripheral administration of centrally-acting mAChR agonists is
not evaluated. Here we studied the anti-inflammatory effects of the centrally-acting M1
mAChR agonist xanomeline (Shannon et al., 1994;Farde et al., 1996). This compound has
previously been developed as an experimental therapeutic for the treatment of Alzheimer’s
disease (Shannon et al., 1994;Bodick et al., 1997a;Frederick et al., 2002). In addition, the
efficacy of xanomeline in improving positive and negative syndromes, as well as cognitive
symptom clusters in patients with schizophrenia is considered a breakthrough (Shekhar et
al., 2008;McKinzie and Bymaster, 2012;Jones et al., 2012).We show that peripheral
administration of xanomeline reduces pro-inflammatory cytokine levels, increases survival,
and attenuates sickness behavior in lethal murine endotoxemia. The anti-inflammatory
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effects of xanomeline are brain mAChR-mediated and require intact vagus nerve and splenic
nerve signaling. Xanomeline administration also provides a relatively long-lasting (at least
20h) anti-inflammatory “priming”, associated with alterations in splenic lymphocyte and
dendritic cell proportions, and decreased splenocyte responsiveness to endotoxin. In
addition, xanomeline treatment in a clinically relevant time frame also improves survival in
a murine model of polymicrobial sepsis. These findings extend and advance our
understanding of the neural cholinergic regulation of cytokine responses and inflammation.

2. Materials and Methods
2.1. Animals

Author Manuscript

Male BALB/c mice (24–28g, Taconic) and male Sprague–Dawley rats (300–380g, Charles
River) were used in experiments. Animals were allowed to acclimate for at least two weeks
prior to the corresponding experiment. All animals were housed in standard conditions
(room temperature 22°C with a 12h light–dark cycle) with access to regular chow and water.
All animal experiments were performed in accordance with the National Institutes of Health
Guidelines under protocols approved by the Institutional Animal Care and Use Committee
and the Institutional Biosafety Committee of the Feinstein Institute for Medical Research,
Manhasset, NY.
2.2. Chemicals
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The M1 mAChR agonists xanomeline and AF267B (Fisher et al., 2002;Caccamo et al.,
2006) were synthesized in the laboratory of Medicinal Chemistry at the Feinstein Institute
for Medical Research by following previously published methodology (Supplementary
Figures 1 and 2) and oxalate salt forms of the compounds were used in experiments.
Atropine sulfate and atropine methyl nitrate were purchased from Sigma. Galantamine
(Galantamine hydrobromide) was purchased from Calbiochem.
2.3. Endotoxemia and drug treatment
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Endotoxemia in mice and rats was induced by administering LPS (endotoxin, Sigma L4130
0111:B4, 6 mg/kg, i.p). Groups of animals were treated i.p. with sterile saline (controls), or
different doses of xanomeline or AF267B, 1h prior to endotoxin administration. In other
experiments sterile saline, xanomeline (20 mg/kg) or galantamine (4 mg/kg) were injected
i.p. 20h or 30h prior to endotoxin. Animals were euthanized by CO2 asphyxiation 1.5h after
endotoxin administration, and blood was collected via cardiac puncture for cytokine
determination. In other sets of survival experiments, groups of mice were treated with sterile
saline, xanomeline (i.p.) or AF267B (i.p.) 1h prior to endotoxin (6 mg/kg, i.p.) injection.
Where indicated in cytokine analysis and survival experiments, mice were pretreated with
atropine sulfate or atropine methyl nitrate (4 mg/kg, i.p.) 15 min prior to xanomeline
treatment. Mice were monitored for survival and clinical manifestations of endotoxemia,
including lethargy, piloerection, and huddling twice daily for the first 7 days, and then daily
for the remainder of the 14 day experiments.
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2.4. Vagotomy
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Cervical unilateral (right side) vagotomy was performed as previously described (Pavlov et
al., 2009). Mice were anesthetized by isoflurane inhalation and the right cervical vagus
nerve was exposed, ligated with a 4-0 silk suture, and divided. In sham-operated animals,
the cervical vagus nerve was visualized, but neither was isolated from the surrounding
tissues nor transected. All animals were permitted to recover for 7 days following the
surgical procedure and before their inclusion in endotoxemic experiments.
2.5. Splenic nerve transection

Author Manuscript

Splenic nerve transection was performed as previously described (Rosas-Ballina et al.,
2008). Rats were anesthetized with 100 mg/kg ketamine and 10 mg/kg xylazine and the
peritoneal cavity was accessed through a midline abdominal incision. After the main
branches of the splenic vessels were identified and isolated, the splenic nerve, which
traverses along the splenic artery, was incised at several points with forceps. In shamoperated rats, the splenic vessels were isolated, but the nerve was left intact. Animals were
permitted to recover for 7 days following the surgical procedure and before their inclusion in
endotoxemic experiments. To assess the efficacy of splenic nerve transection, spleens were
treated with the glyoxylic acid to visualize the catecholaminergic fibers (de la Torre,
1980;Rosas-Ballina et al., 2008). Only animals whose spleens showed complete absence of
catecholamines were included in the analysis.
2.6. Spleen and blood sample preparations for flow cytometry analysis
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Spleen and whole blood were collected immediately after euthanasia. Whole blood was
obtained by cardiac puncture in EDTA-coated tubes (Capiject ®, Terumo Medical,
Summerset, NJ) and centrifuged (1500rpm for 5min); supernatants were collected and
transferred to dry microcentrifuge tubes and spun again (3000rpm for 5min). Supernatants
were frozen immediately at −80°C until analysis. Spleens were collected under aseptic
technique and processed as described previously (Valdes-Ferrer et al., 2013b). In brief,
spleens were flushed with 1ml of sterile PBS+0.5mM EDTA (PBE) and cells extracted by
gentle pressure between glass slides. The obtained material was then resuspended in 10ml of
PBE and passed through a 40µm filter, and centrifuged at 1500rpm for 5 min. In order to
eliminate RBCs, the cell pellet was resuspended in 10ml of lysis buffer (5PRIME, Hamburg,
Germany) for 10min on ice. Cells were washed once with PBS and counted. For cell
analysis, 105 cells were incubated for 15min in 50µl of staining buffer with Fc block (BD
biosciences, San Jose, CA). Cells were stained for flow cytometry using various
combinations of the following antibodies: FITC-conjugated Rat anti-Mouse CD3 (BD
Biosciences, San Jose, CA); PE-Cy7-conjugated Rat anti-Mouse CD19 (BD Biosciences,
San Jose, CA); FITC-conjugated Rat anti-Mouse Ly-6C (eBioscience, San Diego, CA);
Pacific Blue-conjugated Rat anti-Mouse CD11b (BD Biosciences, San Jose, CA); PEconjugated Rat anti-Mouse CD11b (BD Biosciences, San Jose, CA); PE -conjugated Rat
anti-Mouse Ly-6G (BD Biosciences, San Jose, CA); APC-conjugated CD11c (BD
Bioscience, San Jose, CA); and PE-Cy7-conjugated Rat anti-Mouse F4/80 (eBioscience, San
Diego, CA). Data were acquired using a LSRII flow cytometer (BD Biosciences, San Jose,
CA), and analyzed with FlowJo version 9.0 (Tree Star, Inc). Five cell groups were
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characterized as previously described (Valdes-Ferrer et al., 2013b;Swirski et al.,
2009;Eberlein et al., 2010): B-cells (CD3neg, CD19+); T-cells (CD3+, CD19neg); dendritic
(DC) cells (CD11b+, F4/80+, Ly-6G+, CD11c+)cells; polymorphonuclear (PMN) cells
(CD3neg, CD19neg, CD11b+, Ly-6G+); and monocytes (CD3neg, CD19neg, CD11b+,
Ly-6Gneg, Ly-6C+)/macrophages (CD11b+ F480+)
2.7. Ex-vivo endotoxin challenge
Splenocytes were isolated as previously described (Valdes-Ferrer et al., 2013a). Ex-vivo
challenge was performed in RPMI supplemented with 10% FCS, penicillin 100 U/mL, and
streptomycin (100 µg/mL; Gibco). 2×105 spleen cells were incubated for 24 h in 200 µL of
medium alone, or medium containing endotoxin (25 ng/ml) in flat-bottom sterile 96 well
plates for 24h at 37°C, 5% CO2. After 24h, supernatants were collected and preserved
immediately at −80°C until analysis.

Author Manuscript

2.8. Cytokine determination
Blood, collected via cardiac puncture immediately after euthanasia was allowed to clot for
1h and 15 min and then centrifuged at 5,000 rpm (1,500×g) for 10 min. Supernatants (sera)
were subsequently collected and kept at −80 °C prior to serum TNF or IL-6 determination
by ELISA (R&D Systems) according to the manufacturer’s recommendations. The ex vivo
endotoxin-induced splenocyte production of TNF, IL-6, IL-10, IL-12p70, IFN-γ, monocyte
chemotactic protein 1 (MCP1, also known as CCL2) was measured by flow cytometry-based
bead assay using the Mouse Inflammation Kit (BD Biosciences, San Jose, CA) and analyzed
using a FACSArray instrument (BD Biosciences, San Jose, CA).
2.9. Cecal ligation and puncture surgery and drug treatment
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A standardized model of cecal ligation and puncture (CLP)–induced severe polymicrobial
sepsis was used (Pavlov et al., 2007;Parrish et al., 2008). Mice were anesthetized using
ketamine 100 mg/kg and xylazine 8 mg/kg, administered intramuscularly. Abdominal access
was gained via a midline incision. The cecum was isolated and ligated with a 6-0 silk
ligature below the ileocecal valve and then punctured once with a 22G needle. Stool
(approximately 1 mm) was extruded from the hole, and the cecum placed back into the
abdominal cavity. The abdomen was closed with two layers of 6-0 Ethilon sutures. An
antibiotic (Imipenem-Cilastatin, 0.5 mg/kg, subcutaneously, in a total volume of 0.5 ml/
mouse) was administered immediately after CLP as part of the resuscitation fluid. In some
experiments mice were injected i.p. with sterile saline or xanomeline (2, 5 or 20 mg/kg) 20h
prior to CLP. In other sets of experiments mice were randomized 24h after CLP and then
two therapeutic regimens of drug treatments were used. In the first regimen, mice were
injected i.p. with either sterile saline or xanomeline (1, 2, 5, or 20 mg/kg, i.p.) twice daily for
3 consecutive days. In the second regimen, mice were injected i.p. with sterile saline or
xanomeline (1 or 2 mg/kg) at 24h, 30h and 46h following CLP. Mice were monitored for
survival and sepsis-associated clinical signs twice daily for the first 7 days, and then daily
for the remaining of 14 day experiments.
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2.10. Statistical analysis
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Values are presented as mean ± SEM. ANOVA, followed by a post-hoc analysis was used
for multiple comparisons. Student's t-test was used for two groups of data comparison.
Survival experiments were analyzed by Log-Rank test. All tests were performed using
GraphPad Prism. P values equal or below 0.05 were considered significant

3. Results
3.1. Peripheral administration of centrally-acting M1 mAChR agonists suppresses
systemic TNF levels and improves survival in endotoxemia through a central mAChRdependent mechanism

Author Manuscript
Author Manuscript
Author Manuscript

We first examined whether intraperitoneal (i.p.) administration of xanomeline alters
systemic pro-inflammatory cytokine responses. Xanomeline was administered 1h prior to a
lethal endotoxin dose (6 mg/kg, i.p.) in mice and serum TNF analyzed 1.5h later.
Xanomeline significantly and dose-dependently reduced serum TNF levels as compared to
control saline-administered mice (Figure 1A). In addition to decreasing serum TNF,
xanomeline dose-dependently lowered serum IL-6 in endotoxemic mice, thus indicating the
broader scope of xanomeline effects on cytokine responses (Supplementary Figure 3). We
next examined whether these effects were associated with improved survival. Xanomeline
i.p. administration 1h prior to endotoxin (6 mg/kg, i.p.) significantly (up to 100%) and dosedependently improved survival as compared to saline administration (Figure 1B). This
improvement of the survival rate by xanomeline treatment was accompanied by marked
alleviation of decreased locomotor activity, lethargy, piloerection, and huddling –
components of sickness behavior, preceding mortality. Furthermore, i.p. treatment with
AF267B, a structurally-different (Supplementary Figure 2) centrally-acting M1 mAChR
agonist (Fisher et al., 2002;Caccamo et al., 2006) 1h prior to endotoxin (6 mg/kg, i.p.), also
resulted in a dose-dependent suppression of serum TNF levels, improved survival
(Supplementary Figure 4A,B), and alleviated sickness behavior in endotoxemic animals. To
evaluate the role of CNS versus peripheral mAChRs in mediating the anti-inflammatory
effects of xanomeline we used atropine sulfate, a mAChR antagonist that crosses the bloodbrain barrier and atropine methyl nitrate, a mAChR antagonist that does not penetrate it. Pretreatment with atropine sulfate (4 mg/kg, i.p.) abolished the suppressing effect of
xanomeline on serum TNF in endotoxemic mice (Figure 1C). Pretreatment with the same
dose atropine methyl nitrate did not significantly alter the magnitude of this antiinflammatory effect (Figure 1C). By using this approach we also found that brain mAChR
mediate the survival-improving effect of xanomeline (Figure 1D). Neither atropine sulfate
nor atropine methyl nitrate administration alone altered significantly survival in
endotoxemia (Supplementary Figure 5). Together these results show the anti-inflammatory
efficacy of a peripherally administered centrally-acting M1 mAChR agonist through a CNS
mAChRs-mediated mechanism.
3.2. Anti-inflammatory effects of xanomeline are mediated through neural signaling to
spleen
A role for the vagus nerve-based cholinergic anti-inflammatory pathway as a
communication circuit translating CNS mAChR-mediated signaling into suppression of
Brain Behav Immun. Author manuscript; available in PMC 2016 February 01.
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excessive peripheral inflammation has been previously suggested (Pavlov et al.,
2006;Pavlov et al., 2009). Suppression of splenic TNF by activation of this cholinergic antiinflammatory pathway has a major contribution to alleviation of systemic inflammatory
responses in endotoxemia (Huston et al., 2006). Therefore, we examined the effect of
xanomeline on splenic TNF levels. Xanomeline (20 mg/kg, i.p.) administered 1h prior to
LPS (6 mg/kg, i.p.) significantly reduced splenic TNF levels as compared to saline
administration (Figure 2A). We next examined whether surgical transection of the vagus
nerve (vagotomy) alters this xanomeline effect. As shown on Figure 2B, in contrast to shamoperated controls, xanomeline administration in animals with cervical unilateral vagotomy
failed to reduce splenic TNF significantly (Figure 2B). Functional interaction between vagus
nerve and splenic nerve signaling is required for the cholinergic anti-inflammatory pathway
in endotoxemic rats (Rosas-Ballina et al., 2008). Therefore, we next studied whether an
intact splenic nerve is required for xanomeline anti-inflammatory effects. Dose dependency
of xanomeline effects in suppressing rat serum and splenic TNF levels was achieved by
administering lower (1–5 mg/kg) drug doses (as compared to doses in mice) prior to
endotoxin (Figure 2C,D). Xanomeline (20 or 10 mg/kg, i.p.) administration resulted in
further dramatic suppression of serum TNF levels (Supplementary Figure 6). While
xanomeline significantly reduced serum TNF levels in sham-operated endotoxemic rats, it
failed to exert this effect in animals with splenic nerve transection (Figure 2E). Accordingly,
in contrast to suppression of splenic TNF in sham-operated endotoxemic animals,
xanomeline failed to significantly lower splenic TNF in rats with splenic nerve transection
(Figure 2F). These results indicate a role of vagus and splenic nerve signaling in mediating
the anti-inflammatory effects of xanomeline.
3.3. Xanomeline administration provides long-term anti-inflammatory “priming”
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To provide insight into the time window of anti-inflammatory protection by xanomeline we
examined whether administration of xanomeline as early as 20h prior to endotoxin alters
cytokine responses. Xanomeline (20mg/kg, i.p.) administered at this early time point
significantly suppressed serum TNF levels (Figure 3A). Administration of this compound
(20 mg/kg, i.p.) 20h before endotoxin also significantly improved survival (Figure 3B).
When xanomeline (20 mg/kg, i.p.) was administered at 30h prior to endotoxin, it failed to
significantly alter the survival rate (Figure 3C). We next tested whether the antiinflammatory efficacy of another approach of brain cholinergic and mAChR-mediated
activation is also retained within comparable time frame. We used galantamine, a centrallyacting cholinesterase inhibitor, whose anti-inflammatory effects require signaling through
brain mAChRs and the vagus nerve (Pavlov et al., 2009). Galantamine (4 mg/kg, i.p.)
injected 20h prior to LPS in mice significantly suppressed serum TNF levels and improved
survival, but failed to affect survival when administered 30h before LPS (Supplementary
Figure 7). We further examined the contribution of the spleen – a major source of TNF and a
target of the cholinergic anti-inflammatory pathway during endotoxemia (Huston et al.,
2006;Rosas-Ballina et al., 2008;Rosas-Ballina et al., 2011) in the anti-inflammatory
“priming” by xanomeline. Xanomeline early (−20h) administration in mice resulted in a
significant increase in the proportion of T cells and a decrease in the proportion of B cells
and dendritic cells in spleen (Figure 3D). In addition, this xanomeline treatment rendered
splenocytes significantly less sensitive to inflammatory activation as demonstrated by lower
Brain Behav Immun. Author manuscript; available in PMC 2016 February 01.
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TNF, IFN-γ, MCP1, IL-6 and IL-10 release from ex vivo endotoxin-stimulated total spleen
cells (Figure 3E). Together these results demonstrate a previously unrecognized priming
anti-inflammatory effect of xanomeline associated with altered splenic leukocyte
subpopulations and reduced splenocyte inflammatory activation.
3.4. Xanomeline improves survival in mice with severe sepsis
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We further evaluated the efficacy of xanomeline in preclinical settings of sepsis, a lethal
syndrome characterized by dysregulated immune responses and a number one killer in the
intensive care units (Vincent et al., 2013). Cecal ligation and puncture (CLP) is a widely
used preclinical model of severe polymicrobial sepsis (Rittirsch et al., 2009). Based on the
long-lasting anti-inflammatory “priming” effect of xanomeline in the context of
endotoxemia we first examined whether xanomeline administration at 20h prior to CLP
alters sepsis severity. Single administration of xanomeline (20mg/kg, i.p.) 20h prior to CLP
resulted in worsened survival rate as compared to the saline-treated group (Figure 4A).
Administration of lower xanomeline doses (5 or 2mg/kg) at the same time point (20h) prior
to CLP did not result in significant survival alterations (Figure 4B). Next, we examined the
therapeutic efficacy of xanomeline in the treatment of mice with already developed severe
sepsis and associated sickness behavior, manifested by lethargy, piloerection, huddling and
malaise. Mice were randomized 24h after CLP and treated with xanomeline or saline. The
highest drug dose (20 mg/kg) tested in the context of endotoxemia did not alter survival in
severe sepsis as compared to saline administration (data not shown). However, treatments
with lower drug doses (2 or 5 mg/kg) initiated 24h after CLP surgery and continued twice
daily for 3 consecutive days significantly improved survival (Figure 4C) and attenuated
sepsis-associated clinical signs. The lack of significant effect of 1 mg/kg xanomeline
indicated the dose-dependency of these drug effects (Figure 4C). Furthermore, drug
administration within a shorter time window, at 24h, 30h and 46h after the CLP surgery, was
sufficient to improve survival dose-dependently (Figure 4D). The improved survival rate
correlated with attenuation of sickness behavior. Together these results indicate that while
single xanomeline administration as a preventive approach is inefficient in alleviating sepsis
severity, drug treatments initiated in a clinically-relevant time frame significantly improve
survival of mice with CLP-induced sepsis.

4. Discussion

Author Manuscript

Here, we show that peripheral administration of xanomeline, a centrally-acting M1 mAChR
agonist triggers neuro-immune interaction that results in a significant antii-nflammatory
protection. In this interaction CNS cholinergic activation through mAChRs is associated
with vagus and splenic nerve signaling, resulting in suppression of excessive cytokine
responses, alleviated sickness behavior, and improved survival.
These results, together with data indicating the anti-inflammatory efficacy of AF267B – a
structurally-different, centrally-acting M1 mAChR agonist, validate targeting brain
mAChRs by a peripherally administered compound as an approach in treating inflammatory
conditions. The “net” effects of peripheral administration of xanomeline, a M1 mAChR
agonist with extensive CNS penetration, in non-anesthetized rodents, are: lower pro-
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inflammatory cytokine levels, improved survival, and mitigated sickness behavior during
lethal inflammation. Previous preclinical studies have reported a transient decrease in animal
locomotor activity following xanomeline administration, mediated through brain mAChRs
(Maehara et al., 2011). This xanomeline effect was also observed in our experiments,
especially after injecting higher drug doses. Interestingly, this temporary xanomeline effect
correlated with attenuation of endotoxin-induced decreased locomotor activity and lethargy.
Xanomeline, as a M1 mAChR agonist, has also been previously shown not to alter body
temperature and cause hypothermia (Shannon et al., 1994), indicating no effect on CNS
temperature regulation, in which the M2 subtype of mAChRs has been implicated (Gomeza
et al., 1999). These findings suggest that xanomeline treatments would not exacerbate
endotoxemia- and sepsis-associated hypothermia (Saito et al., 2003). Our results point to
brain mAChRs as a mediating component of xanomeline anti-inflammatory effects. In
addition to the CNS, mAChRs are expressed in the periphery and on immune cells
(Kawashima et al., 2012). However, immune cell M1/M5 mAChR deficiency has been
associated with decreased TNF and IL-6 secretion (Kawashima et al., 2012), suggesting a
tonic pro-inflammatory role of these receptors.
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Our results also indicate that the anti-inflammatory effects of xanomeline in endotoxemia
require signaling through the vagus nerve and the splenic nerve. Previous studies have
revealed that the vagus nerve is functionally associated with the splenic nerve within the
cholinergic anti-inflammatory pathway, which suppresses splenic TNF during endotoxemia
(Rosas-Ballina et al., 2008;Rosas-Ballina et al., 2011). The right vagus nerve, through
abdominal posterior celiac branches, contributes innervations to the celiac and superior
mesenteric ganglia (Berthoud and Powley, 1993), where the splenic nerve arises (Bellinger
et al., 1989). Accordingly, unilateral (right side) vagotomy has been used in studying the
anti-inflammatory role of the vagus nerve (Pavlov et al., 2009;Su et al., 2010;Mirakaj et al.,
2014) to avoid potential lethality associated with cervical bilateral vagotomy. Here we show
that xanomeline significantly suppresses splenic TNF levels, and vagus nerve signaling is a
mediating component because cervical unilateral vagotomy significantly attenuated this
effect. Furthermore, splenic nerve transection also resulted in reduced anti-inflammatory
efficacy of xanomeline. These results indicate that xanomeline can be regarded as a brain
activator of the cholinergic anti-inflammatory pathway.
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Previous studies have shown a complex interaction between xanomeline and the M1
mAChR (Christopoulos et al., 1998;Grant et al., 2010). This interaction is characterized by
binding of xanomeline to the orthosteric and an allosteric site of the receptor molecule,
which results in wash-resistant long-term M1 mAChR modulation (Christopoulos et al.,
1998;Grant et al., 2010). A recent study has shown that the longterm modulation of the M1
AChR by xanomeline is abolished by blockade of the orthosteric site of the receptor
molecule by atropine, without affecting the persistent binding of xanomeline to an allosteric
site (Grant et al., 2010). Here we report that the anti-inflammatory activity of xanomeline is
retained for as long as 20h. The role of the previously described unique modulation of the
M1 mAChR by xanomeline in this long-term anti-inflammatory “priming” by xanomeline
remains to be elucidated. However, our findings demonstrating anti-inflammatory priming
within the same time frame with the centrally-acting cholinesterase inhibitor galantamine
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suggests that this is not an effect unique for xanomeline. Here, we also show that the longterm anti-inflammatory effects of xanomeline are associated with increased percentage of T
cells in spleen. This finding is in line with the important role of splenic T cells as a
necessary cellular mediator of the cholinergic anti-inflammatory pathway (Rosas-Ballina et
al., 2011). Therefore, increased splenic T cell subpopulation might be regarded as a
peripheral point for retention of long-term xanomeline anti-inflammatory signaling, which
ultimately correlates with lower pro-inflammatory cytokine production as indicated in this
present study.

Author Manuscript
Author Manuscript

While endotoxemia is a model of robust systemic release of TNF with deleterious
consequences, TNF production at early phases of CLP-induced sepsis has been associated
with beneficial effects, including facilitated phagocytosis of bacteria by immune cells and
confinement of the inflammatory process (Echtenacher et al., 1990). Therefore, whereas
suppressing TNF release in endotoxemia is beneficial, targeted upregulation or suppression
of this cytokine at early stages of CLP-induced sepsis has been related to decreased or
increased mortality respectively (Echtenacher et al., 1990;Echtenacher et al.,
1995;Echtenacher and Mannel, 2002). In contrast to improving survival in endotoxemia, the
early (−20h) administration of xanomeline (20 mg/kg) failed to improve survival in CLPinduced sepsis and even worsened it. Although the effect of xanomeline on cytokine release
in this model was not studied, one could relate this finding to a TNF suppressing effect of
xanomeline as shown in endotoxemia. While preventing sepsis is important, treating sepsis
is undoubtedly one of the most challenging tasks in the intensive care units, and specific
pharmacotherapy is currently lacking. Accordingly, mortality of sepsis remains high. Here
we show that xanomeline treatments of mice with established CLP-induced sepsis,
manifested by peritonitis and characteristic sickness behavior, significantly improve survival
and attenuate behavioral manifestations of sepsis. The previously indicated demonstrated
lack of xanomeline effect on body temperature The lack of These observations indicate the
therapeutic advantage that a centrally-acting mAChR agonist administration provides in
preclinical settings of sepsis. Xanomeline administration within 24h–46h after the onset of
sepsis resulted in similar protection against mortality as the extended 3 day treatment, which
suggests the importance of this time window. These findings add xanomeline to other
cholinergic modalities which improve survival in preclinical sepsis in a clinically-relevant
time frame (Pavlov et al., 2007;Huston et al., 2007;Parrish et al., 2008). In this study, lower
doses of xanomeline were required to significantly improve survival in severe sepsis as
compared to endotoxemia. A plausible explanation might be that the drug was administered
in mice with already developed sepsis and underlying pathophysiological alterations,
including compromised blood-brain barrier (Hofer et al., 2008;Flierl et al., 2009).
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Clinical studies with xanomeline report alleviation of behavioral disturbances and
improvement of some cognitive aspects in patients with Alzheimer’s disease (Bodick et al.,
1997b), and improvement of positive and negative syndromes, verbal learning and shortterm memory in patients with schizophrenia (Shekhar et al., 2008). Interestingly,
schizophrenia, a disease in which xanomeline has therapeutic effects, is associated with lowgrade peripheral inflammation with a proposed pathogenic role (Meyer et al., 2011). In light
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of our current results one may speculate that anti-inflammatory effects of xanomeline might
contribute to its efficacy in schizophrenia.
In conclusion, these results highlight a xanomeline-activated anti-inflammatory mechanism
involving brain mAChRs and peripheral neural signaling within the cholinergic antiinflammatory pathway that function to suppress lethal inflammation. Our findings are of
interest for further studying centrally-acting M1 mAChR agonists as experimental
therapeutic agents in a broader spectrum of inflammatory conditions.
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Figure 1. Xanomeline suppresses serum TNF levels and improves survival in endotoxemia
through a CNS mAChR-mediated signaling
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(A) Xanomeline (X) (5, 10, 20 mg/kg, i.p.) treatment 1h prior to endotoxin (6 mg/kg, i.p.)
administration dose-dependently reduces serum TNF as compare to saline (S) treated
controls (n=5–7 per group, *P<0.001, **P<0.0001) (B) Xanomeline (X) (5, 20 mg/kg, i.p.)
dose-dependently improves survival in murine endotoxemia (n=17–20 per group,
*P<0.0001) (C) Atropine sulfate (AS), but not atropine methyl nitrate (AMN) abolishes
xanomeline (X) suppressive effect on serum TNF (n=8–10 per group, *P<0.0001) (D)
Atropine sulfate (AS), but not atropine methyl nitrate (AMN) abolishes survival
improvement by xanomeline (X) in endotoxemia (n=10 per group, *P<0.0001). Mice were
pre-treated with AS (4 mg/kg, i.p.) or AMN (4 mg/kg, i.p.) 15 min prior to xanomeline (20
mg/kg, i.p.).
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Figure 2. Anti-inflammatory effects of xanomeline during endotoxemia are vagus nerve- and
splenic nerve-dependent

(A) Xanomeline (X) reduces splenic TNF (n=8–10 per group, *P<0.003) in endotoxemic
mice as compared to saline (S) treated controls. (B) Xanomeline reduces splenic TNF in
sham-operated mice, but not in mice with vagotomy (n=8–10 per group, *P<0.001) (C)
Xanomeline i.p. administration in rats suppresses serum TNF levels during endotoxemia
(n=5–7 per group, *P<0.03, **P<0.003). (D) Xanomeline i.p. administration in rats
suppresses splenic TNF levels (n=5–7 per group, *P<0.03). (E) Xanomeline (X) i.p.
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administration suppresses serum TNF in sham-operated animals, but not in rats with splenic
nerve transection (SNT) (n=4–6 per group, *P<0.02) (F) Xanomeline (X) i.p. administration
suppresses splenic TNF in shamoperated animals, but not in rats with splenic nerve
transection (SNT) (n=4–6 per group, *P<0.03).
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Figure 3. Xanomeline treatment provides a long-lasting anti-inflammatory protection associated
with specific changes in the proportions of spleen cell subpopulations and cytokine
responsiveness

(A) Xanomeline (X, 20 mg/kg) i.p. injection in mice 20h prior to endotoxin (6 mg/kg, i.p.)
lowers serum TNF levels as compared to saline (S) (n=8 per group, *P<0.005) (B)
Xanomeline (X, 20 mg/kg) i.p. injection in mice 20h prior to endotoxin (6 mg/kg, i.p.)
improves survival as compared to saline (S) (n=10 per group, *P<0.005) (C) Xanomeline
(X, 20 mg/kg) i.p. injection in mice 30h prior to endotoxin (6 mg/kg, i.p.) does not alter
survival as compared to saline (S) (n=10 per group) (D) Xanomeline (X, 20 mg/kg) i.p.
injection in mice 20h prior to euthanasia alters the proportions of splenocyte subpopulations
as compared to saline (S) injection (n=6 per group, *P<0.04, **P<0.02, ***P<0.01) (E)
Xanomeline (X, 20 mg/kg) i.p. injection in mice 20h prior to euthanasia alters splenocyte
cytokine production in response to endotoxin (n=6 per group, *P<0.03, **P<0.003,
***P<0.0005, ****P<0.0001)
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Figure 4. Delayed xanomeline treatment improves survival in CLP-induced severe sepsis
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(A) Xanomeline (X, 20 mg/kg) i.p. injection in mice 20h prior to cecal ligation and puncture
(CLP) worsens survival as compared to saline (S) (n=15 per group, *P<0.05) (B)
Xanomeline (X, 2 or 5 mg/kg) i.p. injection in mice 20h prior to CLP does not alter survival
as compared to saline (S) (n=22–24 per group) (C) Xanomeline (X, 1, 2, or 3 mg/kg) i.p.
injection, initiated 24h following CLP and continued twice daily for 3 consecutive days
improves survival as compared to saline (n=26–28 per group, *P<0.04) (S) (D) Xanomeline
(X, 1 or 2 mg/kg) injected i.p. at 24h, 30h and 46h after CLP dose-dependently improves
survival as compared to saline (n=27 per group, *P<0.04)
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